The fourth-quarter earnings season for the drug and biotech sector will be in full swing this week with many large drugmakers like — Merck (MRK) , Pfizer (PFE) , Eli Lilly and Company (LLY) , Amgen (AMGN) and Bristol Myers Squibb (BMY) — due to announce results. Johnson & Johnson and AbbVie have already reported with both beating estimates for both earnings and sales. French drugmaker Sanofi came out with disappointing fourth-quarter results as it missed estimates for both earnings and sales.Find the latest ...

The fourth-quarter 2024 reporting cycle of the Medical sector is in full swing. The sector primarily comprises pharma/biotech and medical device companies.See the Zacks Earnings Calendar to stay ahead of market-making news.The earnings season for the medical sector kicked off late last month when pharma giant J&J reported fourth-quarter earnings. Though J&J’s earnings and sales beat estimates, its 2025 sales guidance fell below expectations. Last week, several pharma big-wigs like AbbVie, Novartis, Roche an ...

THOUSAND OAKS, Calif., Jan. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of ...

Wall Street analysts forecast that Amgen (AMGN) will report quarterly earnings of $5.01 per share in its upcoming release, pointing to a year-over-year increase of 6.4%. It is anticipated that revenues will amount to $8.86 billion, exhibiting an increase of 8.1% compared to the year-ago quarter.The current level reflects an upward revision of 0.7% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their ini ...

The fourth-quarter 2024 earnings cycle is here, with quite a few healthcare companies having reported results. Early reports indicate several key growth drivers at play, including increased patient volumes, utilization, admissions, patient days and rate hikes, as well as growing demand for commercial healthcare plans and technology-enabled offerings. However, rising medical costs due to increased utilization and occupancy have partly offset the positives.Based on our exclusive research and unique market ins ...

Company Overview - Amgen is one of the largest biotech companies globally, with a strong presence in various therapeutic areas including oncology, cardiovascular disease, neuroscience, inflammation, bone health, and nephrology [11] - The company has developed significant drugs such as Epogen and Neupogen, and has launched next-generation products like Aranesp and Neulasta [11] - Amgen's acquisition of Immunex Corporation provided access to the blockbuster drug Enbrel, although older drugs are facing declining sales due to competition from biosimilars [11] Financial Performance - Amgen is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of B [12] - The company has a Momentum Style Score of A, with shares increasing by 8.1% over the past four weeks [12] - Earnings estimates for fiscal 2024 have been revised higher by three analysts in the last 60 days, with the Zacks Consensus Estimate increasing by $0.05 to $19.56 per share [12] - Amgen has an average earnings surprise of 4.1% [12] Investment Potential - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, Amgen is recommended for investors' consideration [13]

Core Insights - The European Commission has approved BLINCYTO® (blinatumomab) as part of consolidation therapy for adult patients with newly diagnosed Philadelphia chromosome-negative CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL) [1][7] - The approval is based on the Phase 3 E1910 clinical trial, which demonstrated that adding BLINCYTO to multiphase consolidation chemotherapy significantly improved overall survival compared to chemotherapy alone [2][3] Company Overview - Amgen is a biotechnology company that discovers, develops, manufactures, and delivers innovative medicines, with a focus on treating serious diseases [9] - The company has been recognized as one of the "World's Most Innovative Companies" and is part of the Dow Jones Industrial Average and Nasdaq-100 Index [10] Industry Context - Acute lymphoblastic leukemia (ALL) is a fast-growing blood cancer, with B-ALL being the most common subtype, constituting approximately 75% of cases in adults [4] - The prevalence of ALL in Europe is estimated at 1.28 persons per 100,000 people [4] Product Information - BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE®) immuno-oncology therapy, targeting CD19 surface antigens on B cells to enhance the immune response against cancer [5][8] - In the EU, BLINCYTO is indicated for various patient groups, including adults with newly diagnosed Philadelphia chromosome-negative CD19-positive B-ALL as part of consolidation therapy [6][13]

Core Viewpoint - Amgen is expected to exceed earnings expectations for the fourth quarter and full year 2024, with a consensus estimate of $8.84 billion in sales and $5.01 per share in earnings [1] Group 1: Sales Performance - Strong volume growth is anticipated for Amgen's products, including Evenity, Repatha, Prolia, Kyprolis, and Blincyto, although prices are expected to decline due to increased rebates [2] - The Zacks Consensus Estimate for sales of Prolia, Repatha, Evenity, and Blincyto is $1.18 billion, $551 million, $413 million, and $339 million, respectively [2] - Estimates for Prolia, Repatha, and Evenity sales are $1.05 billion, $542.9 million, and $418.3 million, respectively, with Tezspire and Tavneos contributing $274.4 million and $102.9 million to top-line growth [3] Group 2: New Product Launches - The U.S. launch of Imdelltra for advanced small cell lung cancer is progressing well, with a 200% sequential growth in the third quarter, expected to continue into the fourth quarter [4] - Tepezza sales are projected to be flat to slightly down, with efforts to reorganize and expand the sales force targeting low clinical activity score patients [6] Group 3: Financial Estimates - The Zacks Consensus Estimate for Otezla is $611 million, while the estimate for Enbrel is $861 million, with Amgen's estimates being $605.4 million and $874.5 million, respectively [5] - Adjusted EPS for the fourth quarter is expected to be lower than the third quarter due to historically high R&D costs [7] Group 4: Pipeline Developments - Updates on the pipeline candidate MariTide for obesity are anticipated, with recent phase II study results showing an average weight loss of approximately 20% over 52 weeks, which fell short of investor expectations [8] Group 5: Earnings Surprise History - Amgen has a strong earnings surprise history, with an average surprise of 4.10% over the last four quarters, although the stock has declined 10.6% over the past year [10]

Company Overview - Amgen is one of the largest biotech companies globally, with a strong presence in various therapeutic areas including oncology, cardiovascular disease, and neuroscience [12] - The company has developed successful drugs such as Epogen and Neupogen, and has launched next-generation products like Aranesp and Neulasta [12] - Amgen's acquisition of Immunex Corporation provided access to the blockbuster drug Enbrel, although older drugs are facing declining sales due to competition [12] Financial Performance - Amgen has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a solid position in the market [13] - The company has a Value Style Score of B, supported by a forward P/E ratio of 13.66, which is attractive for value investors [13] - For fiscal 2024, the Zacks Consensus Estimate for earnings has increased by $0.05 to $19.56 per share, with an average earnings surprise of 4.1% [13] Investment Potential - With a solid Zacks Rank and top-tier Value and VGM Style Scores, Amgen is recommended for investors' consideration [14]

Core Viewpoint - Amgen is expected to report a year-over-year increase in earnings and revenues for the quarter ended December 2024, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate for Amgen's quarterly earnings is $5.01 per share, reflecting a year-over-year increase of 6.4% [3]. - Revenues are projected to reach $8.84 billion, which is a 7.9% increase from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 0.17%, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Amgen is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of 3.15% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [8]. - Amgen currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Amgen exceeded the expected earnings of $5.11 per share by delivering $5.58, resulting in a surprise of 9.20% [12]. - Over the past four quarters, Amgen has consistently beaten consensus EPS estimates [13]. Conclusion - While Amgen is positioned as a strong candidate for an earnings beat, other factors should also be considered when evaluating the stock ahead of its earnings release [16].